Ga 68 PSMA-11 in Biology-Guided Radiotherapy for Prostate Cancer

Chunhui Han, PhD, medical physicist in the Department of Radiation Oncology at City of Hope National Medical Center, discusses the potential feasibility of the integration of Gallium 68 (Ga 68) PSMA-11 in biology-guided radiotherapy (BgRT) for patients with prostate cancer with bony metastases.

Biology-guided radiotherapy (BgRT) is a new technique being utilized in radiation oncology, potentially offering an innovative approach that leverages radiotracers to precisely target tumor sites.

Han continues the discussion by presenting on the primary challenges foreseen in implementing this technology in clinical practice.

Transcription:

0:09 | Currently it is not clinically approved for treatment of patients [with] metastatic prostate cancer. There is a lot of preclinical work to be done before Ga 68 PSMA-11 can be used clinically. At City of Hope, we use the RefleXion X1 as a radiotherapy machine to do BgRT treatments. We currently use [fludeoxyglucose (FDG)]-labeled radiotracers to deliver BgRT. Ga 68 PSMA-11 has different physical properties compared with [fluorine F 18 piflufolastat ([18F]-DCFPyL)] FDG. So, for it to be used clinically, there has to be some research to be done.

1:27 | As I mentioned, there is a physical property difference between Ga 68 PSMA-11 and 18F. For example, Ga 68 decays faster than 18F. So, that means that the PET signal may gradually become weaker in treatments. That is one challenge for the implementation of Ga 68 in metastatic prostate cancer treatments. Ga 68 preferentially binds with prostate cancer cells that have an overexpression of PSMA. So, that is what makes it ideal to detect and treat metastatic prostate cancer, but there needs to be some preclinical studies to be done before it can be used clinically.

REFERENCE

Tapping the potential of biology-guided radiation technology. News release. City of Hope. February 6, 2024. Accessed November 20, 2024. https://tinyurl.com/3h2es23p